Current Hematologic Malignancy Reports

, Volume 2, Issue 3, pp 161–166

Is BEACOPP better than ABVD?

Article

Abstract

The majority of patients with advanced Hodgkin’s lymphoma are cured with currently available therapy, such as ABVD (Adriamycin [doxorubicin], bleomycin, vinblastine, and dacarbazine). However, almost 20% of patients fail to achieve a complete remission and almost 40% relapse with prolonged follow-up. BEACOPP (bleomycin, etoposide, Adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) was developed by the German Hodgkin’s Study Group to improve on standard therapy by intensifying treatment and substituting the active agent etoposide for vinblastine and dacarbazine. Promising results led to the HD9 trial, in which escalated BEACOPP was superior to COPP/ABVD (cyclophosphamide, vincristine, prednisone, procarbazine/ABVD). Nevertheless, escalated BEACOPP is myelosuppressive and is associated with an increased risk of secondary malignancies. Modifications of BEACOPP have been developed in an attempt to increase efficacy and reduce the adverse effects. Whether BEACOPP should be selected in preference to ABVD may be determined by clinical stage, patient age, and other risk factors. The answer to whether escalated BEACOPP is superior to ABVD will require the results of an ongoing randomized trial.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    DeVita VT Jr, Serpick AA: Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann Intern Med 1970, 73:881–895.PubMedGoogle Scholar
  2. 2.
    DeVita VT Jr, Simon RM, Hubbard SM, et al.: Curability of advanced Hodgkin’s disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 1980, 92:587–595.PubMedGoogle Scholar
  3. 3.
    Santoro A, Bonfante V, Bonadonna G: Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin’s disease. Ann Intern Med 1982, 96:139–143.PubMedGoogle Scholar
  4. 4.
    Bonadonna G, Zucali R, Monfardini S, et al.: Combination chemotherapy of Hodgkin’s disease with Adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975, 36:252–259.PubMedCrossRefGoogle Scholar
  5. 5.
    Santoro A, Bonadonna G, Bonfante V, Valagussa P: Alternating drug combinations in the treatment of advanced Hodgkin’s disease. N Engl J Med 1982, 306:770–775.PubMedCrossRefGoogle Scholar
  6. 6.
    Canellos GP, Anderson JR, Propert KJ, et al.: Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992, 327:1478–1484.PubMedCrossRefGoogle Scholar
  7. 7.
    Bonadonna G, Valagussa P, Santoro A: Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin’s disease. Ann Intern Med 1986, 104:739–746.PubMedGoogle Scholar
  8. 8.
    Klimo P, Connors JM: MOPP/ABV hybrid program: combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin’s disease. J Clin Oncol 1985, 3:1174–1182.PubMedGoogle Scholar
  9. 9.
    Glick JH, Young ML, Harrington D, et al.: MOPP/ABV hybrid chemotherapy for advanced Hodgkin’s disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. J Clin Oncol 1998, 16:19–26.PubMedGoogle Scholar
  10. 10.
    Duggan DB, Petroni GR, Johnson JL, et al.: Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trial. J Clin Oncol 2003, 21:607–614.PubMedCrossRefGoogle Scholar
  11. 11.
    Diehl V, Sieber M, Rüffer U, et al.: BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin’s disease. Ann Oncol 1997, 8:143–148.PubMedCrossRefGoogle Scholar
  12. 12.
    Tesch H, Diehl V, Lathan B, et al.: Moderate dose escalation for advanced stage Hodgkin’s disease using the bleomycin, etoposide, Adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin’s Lymphoma Study Group. Blood 1998, 92:4560–4567.PubMedGoogle Scholar
  13. 13.
    Diehl V, Franklin J, Pfreundschuh M, et al.: Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med 2003, 348:2386–2395.PubMedCrossRefGoogle Scholar
  14. 14.
    Rüffer JU, Ballova V, Glossman J, et al.: BEACOPP and COPP/ABVD as salvage treatments after primary extended field radiation therapy of early stage Hodgkin’s disease—results of the German Hodgkin Study Group. Leuk Lymph 2005, 46:1561–1567.CrossRefGoogle Scholar
  15. 15.
    Dann EJ, Bar-Shalom R, Tamir A, et al.: Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood 2007, 109:905–909.PubMedCrossRefGoogle Scholar
  16. 16.
    Behringer K, Breuer K, Reineke T, et al.: Secondary amenorrhea after Hodgkin’s lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 2005, 23:7555–7564.PubMedCrossRefGoogle Scholar
  17. 17.
    Josting A, Wiedenmann S, Franklin J, et al.: Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin’s disease: a report from the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 2003, 21:3440–3446.PubMedCrossRefGoogle Scholar
  18. 18.
    Behringer K, Josting A, Schiller P, et al.: Solid tumors in patients treated for Hodgkin’s disease: a report from the German Hodgkin Lymphoma Study Group. Ann Oncol 2004, 15:1079–1085.PubMedCrossRefGoogle Scholar
  19. 19.
    Sieber M, Bredenfield H, Josting A, et al.: 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin’s lymphoma: results of a pilot study of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 2003, 21:1734–1739.PubMedCrossRefGoogle Scholar
  20. 20.
    Engert A, Bredenfield H, Döhner H, et al.: Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin’s lymphoma: results of a phase II study. Haematologica 2006, 91:546–549.PubMedGoogle Scholar
  21. 21.
    Engert A, Franklin J, Mueller RP, et al.: HD12 randomized trial comparing 8 dose-escalated cycles of BEACOPP with 4 escalated and 4 baseline cycles in patients with advanced stage Hodgkin lymphoma (HL): an analysis of the German Hodgkin Lymphoma Study Group (GHSG) [abstract]. Blood 2006, 108(pt 1):33a (Abstract 99).Google Scholar
  22. 22.
    Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin’s disease. N Engl J Med 1998, 339:1506–1514.PubMedCrossRefGoogle Scholar
  23. 23.
    Ballova V, Rüffer J-U, Haverkamp H, et al.: A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin’s disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol 2005, 16:124–131.PubMedCrossRefGoogle Scholar
  24. 24.
    Hartmann P, Rehwald U, Salzberger B, et al.: BEACOPP therapeutic regimen for patients with Hodgkin’s disease and HIV infection. Ann Oncol 2003, 14:1562–1569.PubMedCrossRefGoogle Scholar
  25. 25.
    Canellos GP, Duggan D, Johnson J, Niedzwiecki D: How important is bleomycin in the Adriamycin + bleomycin + vinblastine + dacarbazine regimen? J Clin Oncol 2004, 22:1532–1533.PubMedCrossRefGoogle Scholar
  26. 26.
    Martin WG, Ristow KM, Habermann TM, et al.: Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphoma. J Clin Oncol 2005, 23:7614–7620.PubMedCrossRefGoogle Scholar
  27. 27.
    Santoro A, Devizzi L, Bonfante V, et al.: Phase II study with gemcitabine in pretreated patients with Hodgkin’s (HD) and non-Hodgkin’s lymphomas (NHL): results of a multicenter study [abstract]. Proc Am Soc Clin Oncol 1997, 16:21a (Abstract 71).Google Scholar
  28. 28.
    Tesch H, Santoro A, Fiedler F, et al.: Phase II study of gemcitabine in pretreated Hodgkin’s disease: results of a multicenter study [abstract]. Blood 1997, 90(suppl 1):339a (Abstract 1514).Google Scholar
  29. 29.
    Bredenfield H, Franklin J, Nogova L, et al.: Severe pulmonary toxicity in patients with advanced-stage Hodgkin’s disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin: a report of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 2004, 22:2424–2429.CrossRefGoogle Scholar
  30. 30.
    Friedberg JW, Neuberg D, Kim H, et al.: Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin’s disease: unacceptable acute pulmonary toxicity. Cancer 2003, 98:978–982.PubMedCrossRefGoogle Scholar
  31. 31.
    Bartlett N, Niedzwiecki D, Johnson J, et al.: Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin’s lymphoma: CALGB 59804. Ann Oncol 2007, In press.Google Scholar
  32. 32.
    Hutchings M, Loft A, Hansen M, et al.: FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006, 107:52–59.PubMedCrossRefGoogle Scholar
  33. 33.
    Cheson BD, Pfistner B, Juweid ME, et al.: Revised response criteria for malignant lymphoma. J Clin Oncol 2007, 25:579–586.PubMedCrossRefGoogle Scholar
  34. 34.
    Sanchez-Aguilera A, Montalban C, de la Cueva P, et al.: Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood 2006, 108:662–668.PubMedCrossRefGoogle Scholar
  35. 35.
    Diehl V, Brillant C, Engert A, et al.: Recent interim analysis of the HD11 trial of the GHSG: intensification of chemotherapy and reduction of radiation dose in early unfavorable stage Hodgkin’s lymphoma [abstract]. Blood 2005, 106:816a.Google Scholar
  36. 36.
    Fuchs M, Diehl V, Re D: Current strategies and new approaches in the treatment of Hodgkin’s lymphoma [review]. Pathobiology 2006, 73:126–140.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2007

Authors and Affiliations

  1. 1.Georgetown University HospitalWashington, DCUSA

Personalised recommendations